海南医学
海南醫學
해남의학
Hainan Medical Journal
2015年
19期
2879-2881
,共3页
胰腺癌%糖类抗原19-9%糖类抗原242%相关性分析
胰腺癌%糖類抗原19-9%糖類抗原242%相關性分析
이선암%당류항원19-9%당류항원242%상관성분석
Pancreatic cancer%Carbohydrate antigen 19-9%Carbohydrate antigen 242%Correlation analysis
目的 分析肿瘤标志物糖类抗原19-9 (CA19-9)、糖类抗原242 (CA242)与胰腺癌患者术后生存质量的关系,初步探讨胰腺癌患者术后复发的病理机制.方法 采用AXSYM免疫分析仪检测北京市西城区展览路医院60例胰腺癌患者术后血清中CA19-9和CA242含量,比较术后0.5个月、3个月、6个月复发患者和未复发患者的CA19-9和CA242动态水平,并分析随访患者的临床资料和病理特征.以60例健康体检人员为对照组.结果 胰腺癌组患者的CA19-9和CA242水平均较对照组异常升高,其差异有显著统计学意义(P<0.01);术后复发38例,复发组患者的CA19-9和CA242升高率明显高于未复发组,其差异均具有显著统计学意义(P<0.01);术后3个月患者的CA19-9和CA242水平均明显低于术后0.5个月(P<0.05),且此时复发组和未复发组比较差异均无统计学意义(P>0.05);但手术后6个月该两项指标含量较术后3个月明显上升,且复发组明显高于未复发组,差异均有统计学意义(P<0.05).此外,患者的术后生存时间与肿瘤大小、位置、TNM分期、神经浸润、CA19-9与CA242水平均有关系(P<0.05).结论 肿瘤标志物CA19-9与CA242水平含量异常升高是胰腺癌复发的病理机制之一,水平升高越高,病变越严重,预后越差;水平下降越明显,则患者生存期越长.
目的 分析腫瘤標誌物糖類抗原19-9 (CA19-9)、糖類抗原242 (CA242)與胰腺癌患者術後生存質量的關繫,初步探討胰腺癌患者術後複髮的病理機製.方法 採用AXSYM免疫分析儀檢測北京市西城區展覽路醫院60例胰腺癌患者術後血清中CA19-9和CA242含量,比較術後0.5箇月、3箇月、6箇月複髮患者和未複髮患者的CA19-9和CA242動態水平,併分析隨訪患者的臨床資料和病理特徵.以60例健康體檢人員為對照組.結果 胰腺癌組患者的CA19-9和CA242水平均較對照組異常升高,其差異有顯著統計學意義(P<0.01);術後複髮38例,複髮組患者的CA19-9和CA242升高率明顯高于未複髮組,其差異均具有顯著統計學意義(P<0.01);術後3箇月患者的CA19-9和CA242水平均明顯低于術後0.5箇月(P<0.05),且此時複髮組和未複髮組比較差異均無統計學意義(P>0.05);但手術後6箇月該兩項指標含量較術後3箇月明顯上升,且複髮組明顯高于未複髮組,差異均有統計學意義(P<0.05).此外,患者的術後生存時間與腫瘤大小、位置、TNM分期、神經浸潤、CA19-9與CA242水平均有關繫(P<0.05).結論 腫瘤標誌物CA19-9與CA242水平含量異常升高是胰腺癌複髮的病理機製之一,水平升高越高,病變越嚴重,預後越差;水平下降越明顯,則患者生存期越長.
목적 분석종류표지물당류항원19-9 (CA19-9)、당류항원242 (CA242)여이선암환자술후생존질량적관계,초보탐토이선암환자술후복발적병리궤제.방법 채용AXSYM면역분석의검측북경시서성구전람로의원60례이선암환자술후혈청중CA19-9화CA242함량,비교술후0.5개월、3개월、6개월복발환자화미복발환자적CA19-9화CA242동태수평,병분석수방환자적림상자료화병리특정.이60례건강체검인원위대조조.결과 이선암조환자적CA19-9화CA242수평균교대조조이상승고,기차이유현저통계학의의(P<0.01);술후복발38례,복발조환자적CA19-9화CA242승고솔명현고우미복발조,기차이균구유현저통계학의의(P<0.01);술후3개월환자적CA19-9화CA242수평균명현저우술후0.5개월(P<0.05),차차시복발조화미복발조비교차이균무통계학의의(P>0.05);단수술후6개월해량항지표함량교술후3개월명현상승,차복발조명현고우미복발조,차이균유통계학의의(P<0.05).차외,환자적술후생존시간여종류대소、위치、TNM분기、신경침윤、CA19-9여CA242수평균유관계(P<0.05).결론 종류표지물CA19-9여CA242수평함량이상승고시이선암복발적병리궤제지일,수평승고월고,병변월엄중,예후월차;수평하강월명현,칙환자생존기월장.
Objective To analyze the correlation between tumor marker carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 242 (CA242) and postoperative life quality of patients with pancreatic cancer, and to evaluate the pathogenesis of pancreatic cancer recurrence. Methods Sixty patients with pancreatic cancer hospitalized in Beijing Zhanlanlu Hospital were analyzed with AXSYM immune analyzer. The serum CA19-9 and CA242 levels of 0.5 month, 3 months, 6 months after treatment were compared between patients with and without recurrence. Furthermore, the clinical data and pathological features of patients were also analyzed. And 60 healthy volunteers were selected as con-trol group. Results The CA242 and CA19-9 levels of pancreatic cancer patients were higher than those of healthy vol-unteers, and the differences were statistically significant (P<0.01). The CA19-9 and CA242 levels in recurrence group (38 cases) were higher than those in non-recurrence group (P<0.01). The CA19-9 and CA242 levels were significantly lower at 3 months than 0.5 month after treatment, and there was no statistically significant difference between the recur-rence and non-recurrence group (P>0.05). The CA19-9 and CA242 levels were significantly higher at 6 months than 3 months after treatment, and the levels in recurrence group were higher than those in non-recurrence group (P<0.05). In ad-dition, the survival time of patients was correlated with preoperative tumor size, location, TNM staging, neural invasion, CA19-9 and CA242 levels (P<0.05). Conclusion The increase of CA19-9 or CA242 levels is one of the pathological mechanisms for recurrence of pancreatic cancer. The severity of pancreatic cancer is positively associated with CA19-9 and CA242 levels. With the decrease of CA19-9 and CA242 levels, patient's survival time becomes longer.
